A urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published April 18 in JAMA Oncology.
Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
